[133 Pages Report] Autoinjectors are used to self-administer drugs for the treatment of various diseases and conditions, such as rheumatoid arthritis, multiple sclerosis, diabetes, and anaphylaxis. Autoinjectors are easy to use, portable, and improve dosing accuracy, making them one of the most popular methods for the self-administration of drugs.

The autoinjectors market is projected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2%. Growth in the global autoinjectors market is mainly driven by factors such as the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, the increasing number of regulatory approvals, the availability of generic versions of autoinjectors, favorable reimbursements and government support, and technological advancements in autoinjector devices. The patent expiry of biologics in the coming years is also expected to provide growth opportunities for players in the autoinjectors market.

Disposable autoinjectors segment is expected to grow at the highest CAGR during the forecast period.

Disposable autoinjectors are the most-preferred autoinjectors due to their ease of use and the presence of a built-in glass syringe (eliminates the need for manually loading the glass syringe), which makes it more convenient for patients with reduced dexterity or visual impairments.

The rheumatoid arthritis segment to account for the largest share of the autoinjectors market.

The demand for autoinjectors for this therapy segment is fueled by the increasing incidence of RA across the globe. According to the CDC, an estimated 43.7 million adults (22.7% of the total population) in the US annually are affected by some form of arthritis, RA, gout, lupus, or fibromyalgia. By 2040, an estimated 78 million (26%) US adults aged 18 years or older are projected to have doctor-diagnosed arthritis.

Home care settings to dominate the autoinjectors market during the forecast period

A majority of autoinjectors are used for self-administration of drugs and are rarely recommended for hospital use to avoid the risk of infection due to use on multiple patients. This is a major factor in driving the market growth. Other factors such as the growing prevalence of chronic diseases and technological advancements are also boosting this market segment.

North America to witness the highest market growth during the forecast period

The large share of the North American autoinjectors market can primarily be attributed to the rising prevalence of autoimmune and chronic diseases, increasing prevalence of anaphylaxis, and the increasing number of FDA approvals in the region.

Market Dynamics

Driver: Favorable reimbursements and government support

In the US, autoinjectors are covered on a co-payment basis by most insurance plans, including Medicare Part D. These co-payments and preferred statuses vary based on the plan. In addition, savings allied with a preferred brand are different. In Canada, the coverage for autoinjectors varies across provinces, with a majority of provinces providing full reimbursement for these devices. For instance, the Ontario Drug Benefit ODB program reimburses 100% of the cost of allergy shots and epinephrine autoinjectors in Canada.

The favorable reimbursement environment and government support encouraging the use of autoinjectors in these countries are expected to boost the demand for these devices in the coming years.

Restraint: Preference for alternative drug delivery modes

Traditional injectables are invasive and painful modes of drug delivery owing to which patients and care providers are increasingly focusing on alternative routes of drug delivery, such as oral, topical, and nasal routes. Among the various routes of drug delivery, the oral route is the most preferred as it is easy to use, convenient, cost-effective, safe, and acceptable. Moreover, the introduction of needle-free drug delivery devices such as jet injectors also restricts the growth of the autoinjectors market. Antares Pharma, for example, offers jet injectors for the delivery of growth hormone in the US, Europe, Asia, and Japan.

Opportunity: Patent expiry of biologics to drive the demand for biosimilars

Biosimilars were introduced in 2006 by pharmaceutical companies such as Sandoz (Germany), Teva Pharmaceutical Industries Ltd. (Israel), and JCR Pharmaceuticals Co., Ltd. (Japan). The demand for biosimilars has increased significantly, due to their lower costs. The impending patent expiry of many biologic molecules will also serve to drive the demand for biosimilars.

Even insurance companies and governments are favoring the use of biosimilars and generics. For instance, CVS Caremark, a major prescription insurer in the US, has replaced branded injectable drugs such as Copaxone by Teva and EpiPen by Mylan with their generic counterparts Glatiramer Acetate (Auto-injector) by Mylan and Adrenaclick (an auto-injector) by Amedra Pharmaceuticals. Since many injectables for the treatment of chronic diseases are biologics, the expiry of patents and growing support from governments and insurance providers provides an opportunity for growth.

Challenge: Development of autoinjectors for multiple drug viscosities

The biggest challenge faced by original equipment manufacturers (OEM) is developing single-design autoinjectors for multiple drugs and biologics with varying viscosities. Drugs with different viscosities require springs with different physical characteristics such as composition, length, and thickness to create a spring rate that provides enough power to push higher viscosity drugs and biologics through the syringe to the needle. Currently, most pharma OEMs lack the knowledge required to create autoinjectors that are capable of delivering multiple drugs and biologics with varying viscosities. However, players are working on overcoming this problem. MW Industries (US) is currently working on a solution in collaboration with OEM and NPD firms to design an autoinjector for multiple drug viscosities.

Scope of the Report

Report Metric Details Market size available for years 2016�2023 Base year considered 2017 Forecast period 2018�2023 Forecast units USD million and billion Segments covered Therapy, Type, End-User, and Region Geographies covered North America, APAC, Europe, and Rest of the World Companies covered Abbvie (US), Amgen (US), Teva (Israel), Biogen (US), Eli Lilly (US), and Mylan (US) Merck (US), SHL Group (Taiwan), Ypsomed (Switzerland), AstraZeneca (UK), Becton Dickinson and Company (US), Owen Mumford (UK), Novartis (Switzerland), J&J (US), Haselmeier (Switzerland), Consort Medical (France), Antares Pharma (US)

The research report categorizes the autoinjectors market into the following segments and subsegments:

By Therapy

Rheumatoid Arthritis

Multiple Sclerosis

Diabetes

Anaphylaxis

Other Therapies (Cardiovascular Diseases, Migraines, Psoriasis, and Anemia)

By Type

Disposable Autoinjectors

Reusable Autoinjectors

By End-User

Home Care Settings

Hospital & Clinics

By Region

North America US Canada

Europe UK Germany France Rest of Europe

APAC Japan China India Rest of APAC

Rest of the World

Key Market Players

SHL Group, Becton Dickinson and Company, Ypsomed, Owen Mumford, Haselmeier

Recent Developments

In 2018, Abbvie and Samsung Bioepis signed a licensing agreement to launch Humira biosimilar in Europe.

In 2018, Amgen collaborated with Simcere to co-develop and commercialize biosimilars in China.

In 2018, Haselmeier partnered with Common Sensing to develop self-monitoring injector platforms, which will help patients to record the time and amount of every dose.

In 2017, Ypsomed opened a new manufacturing facility in Solothurn (Switzerland). This new facility will focus on the production of injection systems.

In 2017, Johnson & Johnson received FDA approval of SIMPONI for the treatment of adults with active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS).

Critical questions the report answers:

Which are the most significant revenue-generating regions for the market?

What are the significant upcoming trends in the market?

How will the market drivers, restraints, and future opportunities affect the market dynamics?

Which end-user segment is expected to witness maximum growth opportunities during the forecast period?

To speak to our analyst for a discussion on the above findings, click Speak to Analyst